Patents Assigned to Orphazyme A/S
-
Patent number: 11304941Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.Type: GrantFiled: November 27, 2019Date of Patent: April 19, 2022Assignee: Orphazyme A/SInventors: Thomas Kirkegaard Jensen, Marja H. Jaattela
-
Patent number: 11253505Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.Type: GrantFiled: May 20, 2020Date of Patent: February 22, 2022Assignee: Orphazyme A/SInventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs
-
Patent number: 11229633Abstract: The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.Type: GrantFiled: March 23, 2020Date of Patent: January 25, 2022Assignee: Orphazyme A/SInventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Gert Mads Bolwig, Carlos Roberto Camozzi
-
Patent number: 11045460Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.Type: GrantFiled: November 27, 2019Date of Patent: June 29, 2021Assignee: Orphazyme A/SInventors: Thomas Kirkegaard Jensen, Marja H. Jaattela
-
Patent number: 10898476Abstract: Provided herewith are bioactive agents that increase the intracellular concentration and/or activity of one or more heat shock proteins, including Hsp70, for use in the treatment of a disease associated with dysregulation of cholesterol homeostasis.Type: GrantFiled: April 10, 2017Date of Patent: January 26, 2021Assignee: Orphazyme A/SInventors: Thomas Kirkegaard Jensen, Elina Ikonen, Burcin Gungor
-
Patent number: 10709700Abstract: The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.Type: GrantFiled: September 15, 2015Date of Patent: July 14, 2020Assignee: Orphazyme A/SInventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Gert Mads Bolwig, Carlos Roberto Camozzi
-
Patent number: 10543204Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.Type: GrantFiled: December 26, 2017Date of Patent: January 28, 2020Assignee: Orphazyme A/SInventors: Thomas K. Jensen, Marja H. Jaattela
-
Patent number: 10532085Abstract: The present invention relates to a bioactive agent capable of increasing the intracellular concentration and/or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II.Type: GrantFiled: May 19, 2017Date of Patent: January 14, 2020Assignee: Orphazyme A/SInventors: Thomas K. Jensen, Anders Mørkeberg Hinsby